Group photo2.png
1/1

CEBINA is led by a team of highly experienced academic and medical research scientists and entrepreneurs with decades-long experience in product development and biotech innovation

Management Team

Eszter.jpg
Eszter Nagy, MD, PhD

CEO, CSO Founder

Over 20 years of biotech experience and serial entrepreneurship, successfully raising >€40M VC financing and €16M non-dilutive funding

Co-founder, CEO Calyxha Biotechnologies GmbH; Co-founder, president Eveliqure Biotechnologies GmbH; CEO, CSO Algonist Biotechnologies GmbH

Previously:  Co-founder & CSO Arsanis, Inc (IPO, NASDAQ 2017, now X4 Pharma); SVP Research, Intercell AG (now Valneva SAS)

Wolfgang.jpg
Mag. Wolfgang Friedl

Chief Operating Officer

CEBINA operations, facility, investor relations and legal

Attorney at Law, founder and senior partner of Vienna Legal Group; CEO MAG-LAB

Over 25 years experience in corporate law, national / international M&A, and financing with a strong focus on biotech

Sophie_edited.jpg
Sophie Zettl, PhD

Chief Business Officer

Business development, intellectual property, PR and communications

Over 15 years licensing / BD / IP experience in biotech, Pharma and University Technology Transfer Offices​; CBO, COO Algonist Biotechnologies GmbH

 

Previously: Arsanis Inc, MedImmune / AstraZeneca, University College London, King’s College London

Gabor.jpg
Gábor Nagy MD, PhD

VP Research & Technology Evaluation

14 years biotech R&D experience

 

Previously: Arsanis Inc, Eveliqure Biotechnologies GmbH (co-founder), Intercell AG (now Valneva SAS)

Vali%20ed_edited.jpg
Valéria Szijártó, MD, PhD, MBA

VP Preclinical & Translational Research

10 years biotech R&D experience

Professional MBA in Entrepreneurship and Innovation at WU Executive Academy, Vienna

 

Previously: Arsanis Inc, Eveliqure Biotechnologies GmbH 

Advisors and Investments

Patrick.jpg
Patrick Aisher

Strategic investor / Investment advisor

Chairman of Kinled Holding, serial entrepreneur who has invested in the life science industry since 1997. Focus on biomedical technology companies developing medical devices, biopharmaceuticals, and healthcare services, with direct investments in over 50 businesses, 24 exiting via IPO, trade sale or licensing.

 

Director of Aleva Neurotherapeutics SA, PreComb Therapeutics AG, has identified and invested in early-stage spin-off opportunities from Universities in Barcelona, Zurich, Oxford, Boston, Stanford, NorthEastern, Texas, NYU, Lausanne and Geneva.

January 27, 2020310.jpg
Fabio Blom

Investment Committee Member​

Current open positions